Quarterly report · Q3
4483.TEDINET S100SUYD
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.3bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥8.5bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥19.5bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥7.5bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥5.7bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥2.1bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥2.0bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥4.0bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.0bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥103.6bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥98.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥95.1bn | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥33.6bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥34.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥70.0bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥62.9bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥70.0bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥62.9bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥17.0bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.8bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥9.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥2.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥27.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥62.31 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥20.14 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥44.98 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥19.28 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥60.44 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥19.91 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.66 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥18.45 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 67.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.1% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥102m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2023-12-31 | −¥12m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥102m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2023-12-31 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥515m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2023-12-31 | −¥176m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥301m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.5bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥301m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥50m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥175m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-10-01 → 2023-12-31 | ¥41m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥16.6bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥16.6bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥51m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-10-01 → 2023-12-31 | ¥12m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-10-01 → 2023-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2023-10-01 → 2023-12-31 | ¥556m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥22.4bn |
| —segment total | revenue | 2023-10-01 → 2023-12-31 | ¥8.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥22.3bn |
| —segment total | revenue external | 2023-10-01 → 2023-12-31 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥102m |
| —segment total | revenue intersegment | 2023-10-01 → 2023-12-31 | ¥12m |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥6.7bn |
| —segment total | segment profit | 2023-10-01 → 2023-12-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥417m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2022-12-31 | −¥227m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥944m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥901m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥127m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥310m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥118m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥62m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥19m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥492m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥19.7bn |
| —segment total | revenue | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥19.5bn |
| —segment total | revenue external | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥189m |
| —segment total | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥62m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.7bn |
| —segment total | segment profit | 2022-10-01 → 2022-12-31 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 846
| Item | Context | Value | Unit |
|---|---|---|---|
| Finance costs IFRS | CurrentQuarterDuration | 107000000 | JPY |
| Profit loss before tax IFRS | Prior1QuarterDuration | 1773000000 | JPY |
| Profit loss before tax IFRS | CurrentQuarterDuration | 1957000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第11期第３四半期（自 2023年10月１日 至 2023年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Company name in english cover page | FilingDateInstant | JMDC Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 兼 ＣＥＯ 野口 亮 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)上席執行役員 兼 ＣＦＯ 望月 智洋 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)上席執行役員 兼 ＣＦＯ 望月 智洋 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35308 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 44830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Filer name in english | FilingDateInstant | JMDC Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-12-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |